ALDERIA INTELLIGENCE
← All signals
PubMed16 Apr 2026·BMJ open● 3/10i

Comparison of the effects of eHealth-delivered sedentary breaks versus physical activity promotion interventions on sedentary time: protocol for a systematic review and meta-analysis.

Chen S, Nie X, Giovannucci E, Yang L

A systematic review protocol will compare eHealth-delivered sedentary break interventions versus physical activity promotion for reducing sitting time in adults. The protocol follows PRISMA-P guidelines and will search four databases through July 2025 for randomized controlled trials. This addresses a key evidence gap between two dominant digital health strategies for reducing sedentary behavior, with WHO guidelines emphasizing both increased activity and reduced sitting time. The review will include subgroup analyses by intervention duration, delivery platform, and behavioral change techniques.

Strategic signal

Digital health companies developing sedentary behavior interventions lack clear evidence on optimal strategy selection between break prompts versus activity promotion. This systematic review could establish which approach delivers superior outcomes, potentially shifting product development priorities for companies like Fitbit, Apple Health, and workplace wellness platforms. The findings may influence clinical guidelines and employer health benefit decisions, particularly as remote work increases sedentary time concerns.

Other

Original Abstract

INTRODUCTION: Prolonged sedentary behaviour (SB) is an independent risk factor for adverse health outcomes, with current WHO guidelines emphasising both increased physical activity (PA) and reduced sitting time. While electronic health (eHealth) interventions offer scalable solutions, the comparative effectiveness of two dominant strategies: sedentary break interventions (frequent interruptions of sitting) versus PA promotion (structured activity sessions) remains unclear. This systematic review and meta-analysis protocol aims to compare the effectiveness of interventions targeting breaks in SB versus increased PA in reducing sedentary time through meta-analysis of randomised controlled trials (RCTs) comparing either intervention to a control condition, while exploring key moderating factors including participant characteristics, intervention type, duration, eHealth delivery mode, theoretical basis, use of behaviour change techniques (BCTs), PA intensity and SB frequency. METHODS AND ANALYSIS: This protocol follows the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines. A comprehensive search will be conducted in PubMed, Embase, Web of Science and the Cochrane Library from inception to 31 July 2025, with language restrictions limited to English and Chinese publications. RCTs comparing eHealth-delivered interventions promoting sedentary breaks with those increasing PA in adults will be included. The primary outcome is sedentary time (objectively measured or self-reported), and secondary outcomes include health outcomes such as cardiometabolic markers, fatigue and well-being. Two reviewers (SC and XN) will independently screen studies, extract data and assess risk of bias using validated tools. Meta-analyses will be performed if sufficient homogeneous data are available, comparing changes in sedentary time. Subgroup analyses will explore effects by participant characteristics including gender (male vs female), age groups (<60 vs ≥60 years), intervention type (sedentary breaks vs PA), duration (short-term ≤3 months vs medium-term >3 to <6 months vs long-term ≥6 months), eHealth platform/delivery mode (eg, smartphone apps vs websites vs wearable device prompts vs text messages), theoretical basis (eg, theory-driven interventions vs non-theoretical interventions), use of BCTs (eg, interventions incorporating BCTs vs interventions without BCTs), SB break frequency (eg, every 30 min vs every 60 min) and PA promotion intensity (eg, light vs moderate vs vigorous). A narrative synthesis will be conducted for studies unsuitable for quantitative analysis. ETHICS AND DISSEMINATION: Ethical approval is not required as this study involves secondary analysis of published data. Findings will be disseminated through peer-reviewed publication and conference presentations. PROSPERO REGISTRATION NUMBER: CRD420251042994.

Related signals

ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impact

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Phase 3 trial evaluating retatrutide for chronic low back pain in people with obesity or overweight, targeting dual primary endpoints of pain intensity reduction and weight loss. 586-person placebo-controlled study expected to complete September 2027, investigating a novel indication beyond traditional metabolic endpoints. Eli Lilly is exploring pain management as a potential expansion for their triple agonist, representing the first major trial of a GLP-1-based therapy specifically for chronic pain conditions.

GLP-1Weight lossOtherEli Lilly
ClinicalTrials20 Mar 2026·Phase 3● 7/10i

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Orforglipron is being tested in women with stress urinary incontinence who have obesity or overweight in two phase 3 studies under a master protocol. The trials will enroll 1,000 participants with 58-week follow-up, comparing daily oral orforglipron to placebo. This represents a novel indication expansion for Eli Lilly's small-molecule GLP-1 beyond diabetes and weight management, targeting a large underserved population where weight loss could provide therapeutic benefit. This marks the first major GLP-1 trial in urological conditions, potentially opening a new market segment.

GLP-1OtherEli Lilly
EMA14 Apr 2026·EC Decision — New Marketing Authorisation● 6/10i

EMA: EC Decision — New Marketing Authorisation — Pavblu (aflibercept)

The European Commission approved aflibercept (Pavblu, Amgen) for neovascular age-related macular degeneration, visual impairment from retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization on April 14, 2026. This represents a new marketing authorization following CHMP positive opinion in January 2025. The approval establishes Amgen's entry into the competitive anti-VEGF ophthalmology market, challenging established players Regeneron/Bayer (Eylea) and Roche (Lucentis/Vabysmo) across multiple retinal indications.

FDA19 Mar 2026·Supplemental Approval — Efficacy [Priority Review]● 6/10i

FDA Approves Imcivree (Setmelanotide) — Supplemental Approval — Efficacy [Priority Review]

FDA approved a supplemental application for Imcivree (setmelanotide, Rhythm) on March 19, 2026, under priority review. This represents an efficacy-based label expansion for the melanocortin-4 receptor agonist, which was initially approved for rare genetic obesity disorders. Rhythm gains additional indication breadth in the specialized rare obesity market, where treatment options remain extremely limited. The priority review designation signals FDA recognition of significant unmet medical need in the expanded patient population.

Weight lossOtherRhythm

Weekly briefing

Key signals, decoded for pharma executives and investors. Free, every week.